Change - Announcement of Appointment::Change - Announcement of Appointment

Issuer & Securities

Issuer/ Manager
THOMSON MEDICAL GROUP LIMITED
Securities
THOMSON MED S$175M4.05%N250128 - SGXF89249654 - RMEB
THOMSON MEDICAL GROUP LIMITED - SG1M49904634 - A50
Stapled Security
No

Announcement Details

Announcement Title
Change - Announcement of Appointment
Date &Time of Broadcast
07-Oct-2022 07:43:57
Status
New
Announcement Sub Title
Change - Announcement of Appointment
Announcement Reference
SG221007OTHRLBHW
Submitted By (Co./ Ind. Name)
Foo Soon Soo
Designation
Company Secretary
Description (Please provide a detailed description of the event in the box below)
Appointment of Dr Heng Jun Li Melvin as Executive Director and Group Chief Executive Officer with effect from 1 December 2022

Additional Details

Date Of Appointment
01/12/2022
Name Of Person
Dr Heng Jun Li Melvin
Age
39
Country Of Principal Residence
Singapore
The Board's comments on this appointment (including rationale, selection criteria, board diversity considerations, and the search and nomination process)
The Board of Directors of the Company, having considered the recommendation of the Nominating and Remuneration Committee ("NRC") and having considered Dr Heng's qualifications and work experience, is of the view that Dr Heng possesses the requisite experience and qualifications to assume the position of Executive Director and Group Chief Executive Officer. Accordingly, the NRC recommended, and the Board has approved the appointment of Dr Heng as the Executive Director and Group Chief Executive Officer with effect from 1 December 2022.
Whether appointment is executive, and if so, the area of responsibility
Executive and to oversee the overall strategic planning and business operations and growth of the Group.
Job Title (e.g. Lead ID, AC Chairman, AC Member etc.)
Executive Director and Group Chief Executive Officer
Professional qualifications
Bachelor of Medicine and Bachelor of Surgery ("MBBS"), University of London, St Georges Hospital

Graduate Diploma Occupational Medicine, National University of Singapore

Masters of Business Administration, Frankfurt School of Finance & Management
Any relationship (including immediate family relationships) with any existing director, existing executive officer, the issuer and/ or substantial shareholder of the listed issuer or any of its principal subsidiaries
No
Conflict of interests (including any competing business)
No
Working experience and occupation(s) during the past 10 years
Gleneagles Hospital, IHH Healthcare
Jan 2021 to 31 Oct 2022
Chief Executive Officer

Jul 2019 to Dec 2020
Chief Operating Officer

Sep 2017 to Jun 2019
AVP, Operations

Mesh Bio Pte Ltd
Jul 2018 to Present
Co-Founder & Medical Advisor

Ministry of Health, Singapore
Aug 2016 to Jan 2018
Medical Advisor

Global Health Byte Holdings Pte Ltd (UNO Technologies Pte Ltd)
Jun 2016 to Dec 2018
Investor & Medical Advisor

OneCare Medical Pte Ltd
Aug 2014 to Sep 2017
Equity Partner

Global Medical Concierge Pte Ltd
Jan 2013 to Jun 2017
Co-Founder

Tan Tock Seng Hospital
Jan 2013 to Mar 2015
Medical Doctor, Radiology

National Health Service (United Kingdom)
Jun 2009 to Aug 2011
Medical Doctor
Undertaking submitted to the listed issuer in the form of Appendix 7.7 (Listing Rule 704(7)) Or Appendix 7H (Catalist Rule 704(6))
Yes
Shareholding interest in the listed issuer and its subsidiaries?
No
Other Principal Commitments* Including Directorships#
*"Principal Commitments" has the same meaning as defined in the Code
# These fields are not applicable for announcements of appointments pursuant to Listing Rule 704 (9) or Catalist Rule 704 (8).
Past (for the last 5 years)
- Eracen Pte Ltd (Director)
Present
- Astrid Park Capital Pte Ltd (Director)
- Mesh Bio Pte Ltd (Alternate Director)
(a) Whether at any time during the last 10 years, an application or a petition under any bankruptcy law of any jurisdiction was filed against him or against a partnership of which he was a partner at the time when he was a partner or at any time within 2 years from the date he ceased to be a partner?
No
(b) Whether at any time during the last 10 years, an application or a petition under any law of any jurisdiction was filed against an entity (not being a partnership) of which he was a director or an equivalent person or a key executive, at the time when he was a director or an equivalent person or a key executive of that entity or at any time within 2 years from the date he ceased to be a director or an equivalent person or a key executive of that entity, for the winding up or dissolution of that entity or, where that entity is the trustee of a business trust, that business trust, on the ground of insolvency?
No
(c) Whether there is any unsatisfied judgment against him?
No
(d) Whether he has ever been convicted of any offence, in Singapore or elsewhere, involving fraud or dishonesty which is punishable with imprisonment, or has been the subject of any criminal proceedings (including any pending criminal proceedings of which he is aware) for such purpose?
No
(e) Whether he has ever been convicted of any offence, in Singapore or elsewhere, involving a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, or has been the subject of any criminal proceedings (including any pending criminal proceedings of which he is aware) for such breach?
No
(f) Whether at any time during the last 10 years, judgment has been entered against him in any civil proceedings in Singapore or elsewhere involving a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, or a finding of fraud, misrepresentation or dishonesty on his part, or he has been the subject of any civil proceedings (including any pending civil proceedings of which he is aware) involving an allegation of fraud, misrepresentation or dishonesty on his part?
No
(g) Whether he has ever been convicted in Singapore or elsewhere of any offence in connection with the formation or management of any entity or business trust?
No
(h) Whether he has ever been disqualified from acting as a director or an equivalent person of any entity (including the trustee of a business trust), or from taking part directly or indirectly in the management of any entity or business trust?
No
(i) Whether he has ever been the subject of any order, judgment or ruling of any court, tribunal or governmental body, permanently or temporarily enjoining him from engaging in any type of business practice or activity?
No
(j) Whether he has ever, to his knowledge, been concerned with the management or conduct, in Singapore or elsewhere, of the affairs of :-
(i) any corporation which has been investigated for a breach of any law or regulatory requirement governing corporations in Singapore or elsewhere; or
No
(ii) any entity (not being a corporation) which has been investigated for a breach of any law or regulatory requirement governing such entities in Singapore or elsewhere; or
No
(iii) any business trust which has been investigated for a breach of any law or regulatory requirement governing business trusts in Singapore or elsewhere; or
No
(iv) any entity or business trust which has been investigated for a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, in connection with any matter occurring or arising during that period when he was so concerned with the entity or business trust?
No
(k) Whether he has been the subject of any current or past investigation or disciplinary proceedings, or has been reprimanded or issued any warning, by the Monetary Authority of Singapore or any other regulatory authority, exchange, professional body or government agency, whether in Singapore or elsewhere?
No
Disclosure applicable to the appointment of Director only.
Any prior experience as a director of an issuer listed on the Exchange?
No
If no, please state if the director has attended or will be attending training on the roles and responsibilities of a director of a listed issuer as prescribed by the Exchange
Dr Heng will be briefed on the duties and roles of a director of a listed company upon his appointment. He wil also be attending training on the roles and responsibilities of a director of a listed issuer as prescribed by the Exchange.
Please provide details of relevant experience and the nominating committee's reasons for not requiring the director to undergo training as prescribed by the Exchange (if applicable)
N/A